China Biologic Products Holdings, Inc. (CBPO) Reaches $81.37 After 6.00% Up Move; Profile of 5 Analysts Covering Akorn, Inc. (AKRX)

January 14, 2018 - By Marie Mckinney

The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) is a huge mover today! The stock increased 4.99% or $3.87 during the last trading session, reaching $81.37. About 198,181 shares traded. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 1.48% since January 14, 2017 and is downtrending. It has underperformed by 18.18% the S&P500.The move comes after 5 months positive chart setup for the $2.25 billion company. It was reported on Jan, 14 by Barchart.com. We have $86.25 PT which if reached, will make NASDAQ:CBPO worth $134.82M more.

Among 16 analysts covering Akorn Inc (NASDAQ:AKRX), 5 have Buy rating, 2 Sell and 9 Hold. Therefore 31% are positive. Akorn Inc had 36 analyst reports since July 21, 2015 according to SRatingsIntel. On Friday, February 12 the stock rating was maintained by RBC Capital Markets with “Outperform”. Piper Jaffray maintained it with “Hold” rating and $34.0 target in Tuesday, August 29 report. On Monday, July 17 the stock rating was maintained by Jefferies with “Hold”. WallachBeth Capital maintained it with “Buy” rating and $40 target in Friday, August 5 report. The stock has “Outperform” rating by William Blair on Wednesday, March 23. The stock has “Market Perform” rating by Leerink Swann on Wednesday, March 16. The stock of Akorn, Inc. (NASDAQ:AKRX) earned “Hold” rating by RBC Capital Markets on Sunday, July 30. The firm has “Overweight” rating given on Thursday, September 15 by Piperjaffray. The rating was maintained by Susquehanna on Wednesday, March 23 with “Neutral”. On Friday, November 4 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. See Akorn, Inc. (NASDAQ:AKRX) latest ratings:

05/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $34.0 Maintain
27/10/2017 Broker: Jefferies Rating: Hold New Target: $34.0 Maintain
20/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $34.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $34.0 Maintain
15/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $34.0 Maintain
05/09/2017 Broker: Jefferies Rating: Hold New Target: $34.0 Maintain
01/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $34.0 Maintain
29/08/2017 Broker: Piper Jaffray Rating: Hold New Target: $34.0 Maintain
08/08/2017 Broker: Piper Jaffray Rating: Hold New Target: $34.0000 Maintain
30/07/2017 Broker: RBC Capital Markets Rating: Hold New Target: $34.0000 Maintain

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma biopharmaceutical products to hospitals and inoculation centers in the PeopleÂ’s Republic of China. The company has market cap of $2.25 billion. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. It has a 20.64 P/E ratio. The firm also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus.

Investors sentiment decreased to 0.03 in Q3 2017. Its down 0.62, from 0.65 in 2017Q2. It dropped, as 88 investors sold China Biologic Products Holdings, Inc. shares while 1 reduced holdings. 0 funds opened positions while 3 raised stakes. 1.23 million shares or 91.95% less from 15.29 million shares in 2017Q2 were reported. Public Employees Retirement System Of Ohio has 10,948 shares. Schroder Investment Mgmt Group Incorporated holds 0.16% or 1.02M shares in its portfolio. Matthews International Capital Mgmt Ltd Liability Co reported 41,400 shares. 162,950 were reported by Jupiter Asset Mgmt Limited.

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products had 6 analyst reports since September 4, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 3 by Jefferies. The firm has “Buy” rating by Jefferies given on Friday, October 13. The firm earned “Buy” rating on Tuesday, September 12 by Jefferies. The rating was maintained by Jefferies with “Buy” on Friday, September 4. The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has “Buy” rating given on Monday, June 12 by Jefferies.

Analysts await China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report earnings on February, 22. They expect $1.11 earnings per share, up 56.34% or $0.40 from last year’s $0.71 per share. CBPO’s profit will be $30.65M for 18.33 P/E if the $1.11 EPS becomes a reality. After $1.11 actual earnings per share reported by China Biologic Products Holdings, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: